ALK and non-small cell lung carcinoma: Apart from alectinib which features a promising brain tissue penetration, another second generation ALKi ceritinib is characterized by a relatively high potency against ALK tyrosine kinase compared to crizotinib and alectinib.11, 12 Ceritinib was the first FDA‐approved second generation ALKi for the treatment of ALK‐positive NSCLC.